Top Story Today
A Single LSD Pill Just Outperformed Every Antidepressant on the Market
Definium Therapeutics' LSD-derived drug DT120 beat placebo by 8.1 points on the gold-standard depression scale in Phase 3, a wider gap than any currently approved antidepressant has shown in its own pivotal trials. The kicker: patients took one pill, once, and saw results within a week. Response rates hit 35% versus 7% for placebo, with no serious adverse events reported. There were no mandatory therapy sessions bolted on, just a pharmaceutical-grade tablet administered in a supervised setting. A second pivotal trial is already planned, and multiple analysts projected the stock could climb 50 to 100%.
Why it matters: If a second trial confirms these results, DT120 could become the first psychedelic-derived drug approved without requiring intensive psychotherapy, making it scalable enough to actually reach the hundreds of millions of people living with depression worldwide.
Read more →Clinical Breakthroughs
One Shot to Edit Your DNA Forever. The FDA Might Say Yes.
Intellia's single-dose CRISPR therapy slashed hereditary angioedema attacks by 87% in Phase 3, with 62% of patients going completely attack-free and off all preventive meds. Zero serious adverse events. The company is already filing a rolling application with the FDA, targeting a commercial launch in the first half of 2027. If approved, it would be the first gene-editing medicine that works directly inside the body.
Read more →One Shot a Year: The Tiny Biotech That Just Embarrassed AbbVie
Oruka Therapeutics posted a 63.5% complete skin clearance rate in psoriasis at 16 weeks, numerically beating Skyrizi's best registration trial result of about 40%. The drug may only need one injection per year, compared to Skyrizi's quarterly dosing. Jefferies called it an "outright win" and modeled peak sales between $5 billion and $10 billion. Phase 2a only, though; 63 patients, not thousands.
Read more →Tepezza Just Lost Its $1.9 Billion Monopoly
The FDA approved Viridian's Lumvoa for thyroid eye disease, ending Tepezza's roughly six-and-a-half-year stranglehold on the market. The label covers both active and chronic disease (a first), and treatment takes five infusions over 12 weeks instead of Tepezza's eight over 24. Analysts see 80% stock upside if the launch delivers. A self-injectable version is already in Phase 3.
Read more →FDA and Regulatory Shakeup
The FDA Wants to Watch Your Clinical Trial Live
The FDA launched a pilot to monitor clinical trial data in real time, with AstraZeneca and Amgen as the first participants. The agency explicitly cited competition from China, which has been rapidly closing the gap with the U.S. in early-stage trials. Leadership floated a target of 20 to 40% faster development timelines and signaled a shift toward one well-designed pivotal trial as the default.
Read more →HHS Wants to Shave a Year Off Your Phase 1 Timeline
Operation TrialBlazer aims to cut six to twelve months off Phase 1 prep through rolling IND submissions, clearer manufacturing requirements, a dedicated hotline for sponsors, and modernized dose-selection guidance. The biggest winners: cash-strapped small biotechs burning runway on regulatory paperwork before dosing a single patient. HHS was blunt about the motivation, saying it wants to stop early trials from fleeing to Australia and China.
Read more →The FDA Just Blew Open the Doors to Cancer Trials
Three finalized guidances targeting performance status cutoffs, lab value thresholds, and washout periods will reshape who qualifies for oncology trials. Currently only 2 to 8% of U.S. cancer patients enroll in studies, and 22% of those with a nearby trial get screened out by arbitrary criteria. The new rules demand scientific justification for every exclusion.
Read more →Deals, Outbreaks, and Supply Chain Woes
Lilly Just Bet $1.9B on a Shanghai Biotech. In This Political Climate.
Eli Lilly expanded its partnership with Shanghai-based Abbisko Therapeutics to $1.9 billion in potential payments, gaining global rights to multiple oncology programs. This comes while Congress pushes to decouple U.S. and Chinese biotech. Lilly has now invested roughly $6 billion across Chinese R&D and manufacturing, betting the science outweighs the political risk.
Read more →The Ebola Strain Nobody Built a Vaccine For Is Spreading
The Bundibugyo Ebola strain, which differs from the Zaire strain by over 30%, has infected 2,124 people in the DRC with 828 deaths according to the latest WHO data. No approved vaccine or treatment exists. The U.S. launched a crash vaccine program; CEPI is funding candidates from Moderna, Oxford, and others. A clinical trial testing Mapp Bio's pan-Ebola antibody MBP134 just began in the DRC.
Read more →Lantheus Built a Better Cancer Scanner. The Factory Tanked It.
The FDA rejected Lantheus' cancer imaging kit, but the clinical data was spotless. A third-party manufacturer failed inspection, torpedoing the entire application. Analysts see the problem as fixable. It's a cautionary tale for the booming radiopharmaceutical sector, where manufacturing quality remains a persistent concern.
Read more →